Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Payables (2018 - 2025)

Silence Therapeutics' Payables history spans 8 years, with the latest figure at $13.4 million for Q4 2025.

  • On a quarterly basis, Payables fell 18.56% to $13.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.4 million, a 18.56% decrease, with the full-year FY2025 number at $13.4 million, down 18.56% from a year prior.
  • Payables hit $13.4 million in Q4 2025 for Silence Therapeutics, down from $17.0 million in the prior quarter.
  • Over the last five years, Payables for SLN hit a ceiling of $18.8 million in Q1 2025 and a floor of -$18.9 million in Q2 2024.
  • Historically, Payables has averaged -$3.7 million across 5 years, with a median of -$12.7 million in 2021.
  • Biggest five-year swings in Payables: plummeted 204.11% in 2023 and later surged 241.41% in 2025.
  • Tracing SLN's Payables over 5 years: stood at $14.5 million in 2021, then grew by 1.94% to $14.8 million in 2022, then plummeted by 204.11% to -$15.4 million in 2023, then soared by 206.31% to $16.4 million in 2024, then dropped by 18.56% to $13.4 million in 2025.
  • Business Quant data shows Payables for SLN at $13.4 million in Q4 2025, $17.0 million in Q3 2025, and $14.3 million in Q2 2025.